MARKET

BRVE

BRVE

Braveheart Bio
NASDAQ
27.02
+0.38
+1.43%
Closed 19:30 09/14 EDT
OPEN
26.75
PREV CLOSE
26.64
HIGH
27.76
LOW
26.29
VOLUME
209.18K
TURNOVER
--
52 WEEK HIGH
32.00
52 WEEK LOW
24.31
MARKET CAP
2.43B
P/E (TTM)
-62.7205
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BRVE last week (0907-0911)?
Weekly Report · 1d ago
Goldman Sachs Remains a Buy on Braveheart Bio, Inc. (BRVE)
TipRanks · 5d ago
Analysts Offer Insights on NA Companies: IMAX (IMAX) and Braveheart Bio, Inc. (BRVE)
TipRanks · 6d ago
Braveheart Posts Wider Loss In Q2 As BHB-1893 Advances In HCM Development
NASDAQ · 6d ago
Braveheart Bio Q2 EPS $(2.51)
Benzinga · 6d ago
Braveheart Bio, Inc. reports Q2 results
Seeking Alpha · 6d ago
*Braveheart Bio 2Q Loss/Shr $2.51 >BRVE
Dow Jones · 6d ago
Press Release: Braveheart Bio Reports Second -2-
Dow Jones · 6d ago
More
About BRVE
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.

Webull offers Braveheart Bio stock information, including NASDAQ: BRVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRVE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRVE stock methods without spending real money on the virtual paper trading platform.